

MAH: Evolan Pharma AB	Risk Management Plan	
Name of the medicinal product: Zopiclone 5 mg & 7,5 mg film-coated tablets	Version number: 0.2	1.8.2

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Zopiclone 5 mg & 7,5 mg film-coated tablets (Zopiclone)

This is a summary of the risk management plan (RMP) for Zopiclone 5 mg & 7,5 mg film-coated tablets (hereafter referred as Zopiclone film-coated tablets). The RMP details important risks of Zopiclone film-coated tablets, how these risks can be minimised, and how more information will be obtained about Zopiclone film-coated tablets' risks and uncertainties (missing information).

Zopiclone film-coated tablets' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Zopiclone film-coated tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Zopiclone film-coated tablet's RMP.

I. The medicine and what it is used for

Zopiclone film-coated tablets is indicated for transient and short-term treatment of insomnia in adults. Supportive therapy, for a limited time, for treatment of chronic insomnia in adults.
(See SmPC for full indication).

It contains zopiclone as active substance and is for oral use.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks when taking Zopiclone film-coated tablets, together with measures to minimise such risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

MAH: Evolan Pharma AB	Risk Management Plan	1.8.2
Name of the medicinal product: Risk management system	Version number: 0.2	
Zopiclone 5 mg & 7,5 mg film-coated tablets		

II.A List of important risks and missing information

Important risks of Zopiclone film-coated tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Zopiclone film-coated tablets.

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Zopiclone film-coated tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Zopiclone film-coated tablets.